Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00949117 · OUTCOME

Quality of Life as Assessed by Peds-FAACT Questionnaire at Baseline and at Weeks 4 and 24

Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer · Source last updated 2014-04-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
24 weeks

Analysis population: Outcome not assessed as the one subject that completed the protocol was too young to complete the PedsFAACT quality of life assessment.

Groups in this outcome

Arm I- Cyproheptadine Hydrochloride

Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.

Arm II Cyproheptadine HCl and PediaSure or Ensure

Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (\> 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I- Cyproheptadine Hydrochloride0
Arm II Cyproheptadine HCl and PediaSure or Ensure0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    units
    Participants
groups
  1. description
    Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.
    id
    OG000
    title
    Arm I- Cyproheptadine Hydrochloride
  2. description
    Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (\> 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.
    id
    OG001
    title
    Arm II Cyproheptadine HCl and PediaSure or Ensure
population Description
Outcome not assessed as the one subject that completed the protocol was too young to complete the PedsFAACT quality of life assessment.
reporting Status
POSTED
time Frame
24 weeks
title
Quality of Life as Assessed by Peds-FAACT Questionnaire at Baseline and at Weeks 4 and 24
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice